• Image
    lock
    Science & Innovation / Image
    Mode of Action of a CGRP Receptor Blocker

    Mode of Action of a CGRP Receptor Blocker, calcitonin gene-related peptide (CGRP), CGRP receptor complex, CGRP receptor blocker targeting the receptor complex.

  • Image
    lock
    Leadership / Image
    Marie-France Tschudin

    President, Innovative Medicines International & Chief Commercial Officer

  • Image
    lock
    Science & Innovation / Image
    Malaria Researchers in Nairobi, Kenya

    Malaria researchers in Nairobi, Kenya, are working to stay one step ahead of the malaria parasite in order to provide innovative treatments to support elimination efforts.

  • Image
    lock
    Image
    Malaria Prevention

    Rural village, Lake Victoria region, Kenya: A teacher talks to school children about prevention and proper treatment of malaria. Simple tools like bed nets, effective medicines and indoor spraying have helped some African countries to reduce malaria deaths by 50% or more.

  • Image
    lock
    Image
    Malaria Diagnostic Test

    Rapid Diagnostic Tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites in human blood. They allow the testing of people who cannot access diagnosis based on microscopy.

  • Image
    lock
    Locations / Image
    Hedge and trees along Fabrikstrasse
  • Image
    lock
    Manufacturing / Image
    Farmer Harvesting Artemisia Annua

    In China, Novartis works with about 100,000 farmers who cultivate Artemisia annua, a crucial plant in the production of our antimalarial treatment.

  • Image
    lock
    Manufacturing / Image
    Artemisinin Extraction

    We source our antimalarial treatment’s active pharmaceutical ingredients from China. Once the farming is done, the technical process begins. After the artemisinin has been extracted from the leaves, it is again dissolved in ethanol and processed for higher purity and quality. Here, a facility for the processing of artemisinin.

  • Image
    lock
    Image
    Artemisinin-Combination Therapy (ACT)

    Deliveries of this child-friendly antimalarial hit the 300 million mark. This child-friendly ACT is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT).

  • Image
    lock
    Manufacturing / Image
    Antimalarial Raw Material

    Antimalarial raw material before it is made into pills.

  • Image
    lock
    Manufacturing / Image
    Antimalarial Pills

    Antimalarial pills before being packed

  • Image
    lock
    Locations / Image
    Aerial View of the Basel Campus, Novartis HQ